252 related articles for article (PubMed ID: 37604925)
21. The Role of the Estrogen Pathway in the Tumor Microenvironment.
Rothenberger NJ; Somasundaram A; Stabile LP
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463044
[TBL] [Abstract][Full Text] [Related]
22. Tumor inherent interferons: Impact on immune reactivity and immunotherapy.
Brockwell NK; Parker BS
Cytokine; 2019 Jun; 118():42-47. PubMed ID: 29681426
[TBL] [Abstract][Full Text] [Related]
23. Turning Cold into Hot: Firing up the Tumor Microenvironment.
Duan Q; Zhang H; Zheng J; Zhang L
Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
[TBL] [Abstract][Full Text] [Related]
24. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic Regulations in Autoimmunity and Cancer: from Basic Science to Translational Medicine.
Hui L; Ziyue Z; Chao L; Bin Y; Aoyu L; Haijing W
Eur J Immunol; 2023 Apr; 53(4):e2048980. PubMed ID: 36647268
[TBL] [Abstract][Full Text] [Related]
26. Emerging Epigenetic-Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment.
Zhang J; Huang L; Ge G; Hu K
Adv Sci (Weinh); 2023 Mar; 10(7):e2206169. PubMed ID: 36599655
[TBL] [Abstract][Full Text] [Related]
27. The paradigm of drug resistance in cancer: an epigenetic perspective.
Adhikari S; Bhattacharya A; Adhikary S; Singh V; Gadad SS; Roy S; Das C
Biosci Rep; 2022 Apr; 42(4):. PubMed ID: 35438143
[TBL] [Abstract][Full Text] [Related]
28. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
Loo Yau H; Ettayebi I; De Carvalho DD
Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
[TBL] [Abstract][Full Text] [Related]
29. gC1qR: A New Target for Cancer Immunotherapy.
Lei Y; Li X; Qin D; Zhang Y; Wang Y
Front Immunol; 2023; 14():1095943. PubMed ID: 36776869
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
31. Type I interferons in pancreatic cancer and development of new therapeutic approaches.
Blaauboer A; Sideras K; van Eijck CHJ; Hofland LJ
Crit Rev Oncol Hematol; 2021 Mar; 159():103204. PubMed ID: 33387625
[TBL] [Abstract][Full Text] [Related]
32. Targeting innate sensing in the tumor microenvironment to improve immunotherapy.
Liu Z; Han C; Fu YX
Cell Mol Immunol; 2020 Jan; 17(1):13-26. PubMed ID: 31844141
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic modulation in cancer immunotherapy.
Gallagher SJ; Shklovskaya E; Hersey P
Curr Opin Pharmacol; 2017 Aug; 35():48-56. PubMed ID: 28609681
[TBL] [Abstract][Full Text] [Related]
34. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
35. Macrophages in immunoregulation and therapeutics.
Chen S; Saeed AFUH; Liu Q; Jiang Q; Xu H; Xiao GG; Rao L; Duo Y
Signal Transduct Target Ther; 2023 May; 8(1):207. PubMed ID: 37211559
[TBL] [Abstract][Full Text] [Related]
36. Harnessing type I interferon-mediated immunity to target malignant brain tumors.
Lim J; Kang I; La J; Ku KB; Kang BH; Kim Y; Park WH; Lee HK
Front Immunol; 2023; 14():1203929. PubMed ID: 37304294
[TBL] [Abstract][Full Text] [Related]
37. Intimate communications within the tumor microenvironment: stromal factors function as an orchestra.
Cheng B; Yu Q; Wang W
J Biomed Sci; 2023 Jan; 30(1):1. PubMed ID: 36600243
[TBL] [Abstract][Full Text] [Related]
38. Reinvigorating exhausted CD8
Hossain MA; Liu G; Dai B; Si Y; Yang Q; Wazir J; Birnbaumer L; Yang Y
Med Res Rev; 2021 Jan; 41(1):156-201. PubMed ID: 32844499
[TBL] [Abstract][Full Text] [Related]
39. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
Wang Q; Wu X
Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
